SCH 52365 [Temozolomide] Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

SCH 52365 [Temozolomide] Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 21 Feb 2013 Trial company changed from Schering-Plough to Merck and Co as reported by ClinicalTrials.gov.
    • 12 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top